Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-galectin-1 monoclonal antibody (clone 3)
- Development stage
- Preclinical
- Lead developer
- Instituto de Biología y Medicina Experimental
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
anti-galectin-1 monoclonal antibody (clone 3) is a neutralizing monoclonal antibody specifically designed to target and inhibit Galectin-1 (GAL1), a glycan-binding protein that facilitates tumor progression, immune evasion, and metastatic dissemination. Developed by researchers at IBYME-CONICET and the spin-off Galobio, this antibody (clone 3) has demonstrated the ability to disrupt hormone-driven mammary gland remodeling and early metastatic spreading in preclinical models of HER2+ breast cancer. By blocking GAL1, the antibody reduces the release of early circulating tumor cells (CTCs), decreases the formation of transformed ducts, and significantly curtails lung metastasis. It also appears to modulate progesterone receptor (PR) expression in mammary luminal cells, suggesting a role in regulating hormone-driven epithelial remodeling.
- Other names
- anti-GAL1 mAb (clone 3)anti-Galectin-1 mAbanti-Galectin1 mAbanti-Galectin 1 mAbGAL1 neutralizing monoclonal antibodyGAL-1 neutralizing monoclonal antibodyGAL 1 neutralizing monoclonal antibody
02
Targets
LGALS1 (Galectin-1)
Beyond the preview
Go deeper on anti-galectin-1 monoclonal antibody (clone 3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-galectin-1 monoclonal antibody (clone 3).